Skip to main content

Hereditary Hemorrhagic Telangiectasia (HHT)

2
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Alnylam Pharmaceuticals
1 program
1
ALN-6400Phase 1/21 trial
Active Trials
NCT06659640Recruiting120Est. Jun 2028
Vaderis Therapeutics
Vaderis TherapeuticsSwitzerland - Basel
1 program
1
VAD044 Part IPhase 1/21 trial
Active Trials
NCT05406362Active Not Recruiting75Est. Jan 2027
Utah Medical
Utah MedicalIreland - Dublin
1 program
PomalidomideN/A1 trial
Active Trials
NCT07018401Active Not Recruiting62Est. Jun 2026
Terremoto Biosciences
1 program
TER-1754PHASE_11 trial
Active Trials
NCT07255846Withdrawn0Est. Mar 2028

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
Alnylam PharmaceuticalsALN-6400
Vaderis TherapeuticsVAD044 Part I
Terremoto BiosciencesTER-1754
Utah MedicalPomalidomide

Clinical Trials (4)

Total enrollment: 257 patients across 4 trials

NCT06659640Alnylam PharmaceuticalsALN-6400

A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Start: Nov 2024Est. completion: Jun 2028120 patients
Phase 1/2Recruiting
NCT05406362Vaderis TherapeuticsVAD044 Part I

Assess Safety and Efficacy of VAD044 in HHT Patients

Start: Jul 2022Est. completion: Jan 202775 patients
Phase 1/2Active Not Recruiting
NCT07255846Terremoto BiosciencesTER-1754

A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

Start: Dec 2025Est. completion: Mar 20280
Phase 1Withdrawn
NCT07018401Utah MedicalPomalidomide

Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study

Start: May 2024Est. completion: Jun 202662 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 257 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.